NGM concedes key failure for their lead NASH drug, closing the door on a pivotal followup — and asking analysts to look past the wreckage into the pipeline

A little more than a year ago NGM whipped up considerable enthusiasm for its anti-fibrotic NASH drug aldafermin based on a cohort of patients who …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

NGM con­cedes key fail­ure for their lead NASH drug, clos­ing the door on a piv­otal fol­lowup — and ask­ing an­a­lysts to look past the wreck­age in­to the pipeline